Celltrion Completes Permanent Retirement of 9.11 Million Shares

Celltrion announced on the 14th that the retirement of 9.11 million treasury shares, equivalent to approximately 4% of its total issued shares (valued at approximately 1.7782 trillion won), was finally reflected as of the amended listing on the 13th. This accounts for about 74% of its treasury stock holdings and marks the largest treasury stock retirement in the history of the domestic pharmaceutical and bio industry.

This treasury stock retirement is part of the shareholder return policy and is expected to impact the improvement of investment indicators and performance growth. The reduction in issued shares leads to an increase in earnings per share (EPS) and improvements in key investment indicators such as the price-to-earnings ratio (PER). This positively affects institutional and foreign investor demand.

The retired shares include approximately 3 million shares that were originally intended for use as stock option compensation. In the future, stock option compensation will be converted to new share issuance as needed.